The FDA has designated the viral vector rAAVrh74, which Sarepta Therapeutics, Inc. (NASDAQ:SRPT) uses in its gene therapy ...

Fintel reports that on June 6, 2025, Scotiabank upgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) from Sector ...

The Platform Technology Designation, which predates the current FDA leadership, is designed to streamline the drug ...

With FDA platform technology designation for its viral vector, SRPT can fast-track other therapies using the same ...

The company is one of the first to receive a “platform technology designation,” which could speed the review of certain gene ...

Sarepta Therapeutics (SRPT) stock gains as Scotiabank upgrades it to Sector Outperform ting a compelling risk-reward setup. Read more here.

A Sarepta police officer has been arrested in connection with an incident where a dog was shot and killed last month.

Interim results from a small group of children in a Phase I/II trial are essentially in line with that of Elevidys, according ...

The Webster Parish Sheriff's Office is investigating two officers in two different towns accused of shooting dogs.

US rare disease meds developer Sarepta Therapeutics (Nasdaq: SRPT) revealed that its rAAVrh74 viral vector used in the ...

RegenXBio has shared updated phase 1/2 data on its Duchenne muscular dystrophy (DMD) gene therapy, providing evidence that ...

Sarepta Therapeutics’ gene therapy to treat limb girdle muscular dystrophy type 2E/R4 gets US FDA platform technology designation: Cambridge, Massachusetts Friday, June 6, 2025, ...